Praziquantel
Praziquantel (praziquantel) is a small molecule pharmaceutical. Praziquantel was first approved as Biltricide on 1982-12-29. It is used to treat clonorchiasis, cysticercosis, helminthiasis, opisthorchiasis, and parasitic intestinal diseases amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| digestive system diseases | D004066 |
Trade Name
FDA
EMA
Praziquantel (discontinued: Biltricide)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| biltricide | New Drug Application | 2023-12-06 |
| praziquantel | ANDA | 2024-02-28 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
56 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Schistosomiasis | D012552 | EFO_1001475 | B65 | 1 | 7 | 9 | 4 | 11 | 31 |
| Malaria | D008288 | EFO_0001068 | B54 | — | — | — | 1 | 5 | 6 |
| Schistosomiasis mansoni | D012555 | EFO_1001420 | B65.1 | — | 2 | 1 | 2 | 1 | 6 |
| Taeniasis | D013622 | EFO_1001433 | B68 | — | 2 | 3 | 1 | 1 | 5 |
| Helminthiasis | D006373 | EFO_1001342 | B65-B83 | — | — | — | 1 | 3 | 4 |
| Neurocysticercosis | D020019 | — | — | — | 2 | 3 | 1 | — | 4 |
| Cysticercosis | D003551 | EFO_0007231 | B69 | — | 2 | 3 | 1 | — | 4 |
| Anemia | D000740 | EFO_0004272 | D64.9 | — | — | — | 1 | 2 | 3 |
| Hiv | D006678 | — | O98.7 | — | — | — | 1 | — | 1 |
| Disease susceptibility | D004198 | — | — | — | — | — | 1 | — | 1 |
Show 2 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Schistosomiasis haematobia | D012553 | EFO_0007530 | B65.0 | — | — | 5 | — | 3 | 8 |
| Healthy volunteers/patients | — | — | — | 5 | — | 1 | — | — | 6 |
| Schistosoma haematobium | D012548 | — | — | — | 1 | 3 | — | 1 | 4 |
| Schistosoma mansoni | D012550 | NCBITaxon_6183 | — | — | 1 | 3 | — | 1 | 4 |
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | 1 | — | — | 1 |
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | — | 1 | — | — | 1 |
| Recurrence | D012008 | — | — | — | — | 1 | — | — | 1 |
| Epilepsy | D004827 | EFO_0000474 | G40.9 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | — | 1 | — | — | — | 1 |
| Schistosomiasis japonica | D012554 | EFO_1001419 | B65.2 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Filariasis | D005368 | — | B74 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Infections | D007239 | EFO_0000544 | — | — | — | — | — | 6 | 6 |
| Hiv infections | D015658 | EFO_0000764 | B20 | — | — | — | — | 4 | 4 |
| Communicable diseases | D003141 | — | — | — | — | — | — | 3 | 3 |
| Parasitic diseases | D010272 | EFO_0001067 | B88 | — | — | — | — | 3 | 3 |
| Coinfection | D060085 | — | — | — | — | — | — | 3 | 3 |
| Sexually transmitted diseases | D012749 | — | A50-A64 | — | — | — | — | 1 | 1 |
| Schistosoma | D012547 | — | — | — | — | — | — | 1 | 1 |
| Hematologic diseases | D006402 | EFO_0005803 | D75.9 | — | — | — | — | 1 | 1 |
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | — | — | — | — | 1 | 1 |
| Immunologic deficiency syndromes | D007153 | — | D84.9 | — | — | — | — | 1 | 1 |
Show 10 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Praziquantel |
| INN | praziquantel |
| Description | 2-[cyclohexyl(oxo)methyl]-3,6,7,11b-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4-one is a member of isoquinolines. |
| Classification | Small molecule |
| Drug class | anthelmintics (undefined group): 2-deoxoparaherquamide A derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O=C(C1CCCCC1)N1CC(=O)N2CCc3ccccc3C2C1 |
Identifiers
| PDB | — |
| CAS-ID | 55268-74-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL976 |
| ChEBI ID | — |
| PubChem CID | 4891 |
| DrugBank | DB01058 |
| UNII ID | 6490C9U457 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Praziquantel
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 10,662 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
196 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use